Compare Microchip Technology Inc. (MCHP) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Medtronic PLC — how do they compare? Microchip Technology Inc. trades at $75.02 (market cap $41.01B), while Medtronic PLC trades at $89.1 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 2.7× Microchip Technology Inc.'s market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 62 Days and Medtronic PLC for 63 Days on average.
| MCHP | MDT | |
|---|---|---|
Market Cap | $41.01B | $112.24B |
Volume | 9,972,516 | 105,663,236 |
Sector | Technology | Health |
52-Week High | $102.97 | $105.35 |
52-Week Low | $49.02 | $73.75 |
Typical Hold Time | 62 Days | 63 Days |
Enterprise Value | $46.13B | $131.58B |
Dividend Yield | 2.41% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $78.02, down 3.99% today, amid a bearish technical signal. The company shows mixed fundamentals with strong recent earnings beats but a challenging 2025 with negative net income. Valuation metrics appear elevated with P/E of 111.06 and P/S of 8.08. Recent developments include the acquisition of Hailo and expansion of Ethernet and power portfolios targeting automotive and data center markets.
Outlook remains cautiously optimistic with analyst consensus at $110.50 (41% upside) and no sell ratings. Key opportunities include AI infrastructure demand and inventory normalization, while risks include high debt levels, competitive pressures, and semiconductor cycle volatility. The stock's performance hinges on execution of growth initiatives and market conditions.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
